Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
  • Y02P20/00—Technologies relating to chemical industry
  • Y02P20/50—Improvements relating to the production of bulk chemicals
  • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

• the present invention relates to synthesis procedures and synthesis intermediates of substituted bicyclic compounds, especially compounds that are useful as medicaments, for instance Bruton’s tyrosine kinase (Btk) inhibitors such as ibrutinib.
• Btk tyrosine kinase
• Ibrutinib is an organic small molecule having IUPAC name 1-[(3R)-3-[4-amino-3-(4- phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one. It is described in a number of published documents, including international patent application WO 2008/039218 (Example 1b), and is described as an irreversible inhibitor of Btk. Btk plays an essential role in the B-cell signaling pathway linking cell surface B-cell receptor stimulation to downstream intracellular responses.
• Btk is a key regulator of B- call development, activation, signaling, and survival (Kurosaki, Curr Op Imm, 2000, 276-281; Schaeffer and Schwartzberg, Curr Op Imm 2000, 282-288).
• Btk plays a role in a number of other hematopoetic cell signaling pathways, e.g. Toll like receptor (TLR) and cytokine receptor-mediated TNF-a production in macrophages, IgE receptor (FcepsilonRI) signaling in Mast cells, inhibition of Fas/APO-1 apoptotic signaling in B-lineage lymphoid cells, and collagen-stimulated platelet aggregation.
• TLR Toll like receptor
• FcepsilonRI IgE receptor
• Ibrutinib has been approved for certain hematological malignancies in several countries including the US and the EU, and is also being studied in clinical trials for other hematological malignancies. Such malignancies include chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma and multiple myeloma. There are a number of ways of preparing functionalised bicyclic heterocycles and ibrutinib, which have been described in inter alia US patent document US
• ibrutinib i.e. the pyrazolopyrimidine
• the bicyclic ring itself is built up by preparing a pyrazole intermediate substituted at the 3- and 4- position by an amino and cyano group, respectively, followed by reaction with formamide.
• Other methods for synthesising ibrutinib have been disclosed in international patent application WO 2014/139970, including through the following scheme:
• the core heterobicycle of ibrutinib i.e. the pyrazolopyrimine is built up through an intermediate having a pyrazole ring substituted at the 3- and 4-positions with an amino and cyano group, respectively.
• the pyrimidine part of the core heterobicycle pyrazolpyrimidine can also be built up, and then further functionalised to form ibrutinib.
• the final step to introduce the substituent on the nitrogen atom of the piperidinyl ring may be performed in accordance with the above scheme and may also be performed with procedures described in international patent application WO 2016/115356, by reaction with 3-chloropropionyl chloride (for instance in the presence of aqueous NaHCO3 in Me-THF), thereby introducing a -C(O)-CH 2 CH 2 -Cl group at the nitrogen atom of the piperidinyl.
• Such intermediate then undergoes an elimination reaction in the presence of DBU (1,8-diazabicyclo(5.4.0)undec-7-ene) to provide ibrutinib.
• R 1 represents a nitrogen protecting group
• R 2 represents hydrogen or aryl (e.g. phenyl);
• X 1 represents a substituent selected from a leaving group (e.g. halo, -O-Y 1 , and the like) and -N(R 3 )R 4 ;
• Y 1 represents hydrogen or a sulfone (e.g. -S(O in which R x may represent C 1-3 alkyl optionally substituted by one or more fluoro atoms, or, aryl (e.g. phenyl) optionally substituted by one or more substituents selected from halo and C1-3 alkyl, which latter group may itself be optionally substituted by one or more fluoro atoms) and hence when X 1 represents -O-Y 1 a sulfonate group may be formed, e.g. X 1 may represent a tosylate, mesylate or triflate;
• a sulfone e.g. -S(O in which R x may represent C 1-3 alkyl optionally substituted by one or more fluoro atoms, or, aryl (e.g. phenyl) optionally substituted by one or more substituents selected from halo and C1-3 alkyl, which latter group may itself be optional
• R 3 and R 4 represents a nitrogen protecting group, and the other represents hydrogen, or an independent nitrogen protecting group;
• R 1 , R 2 and X 1 are as hereinbefore defined, in the presence of an oxidant (e.g. a source of oxygen, for instance air and, specifically, O 2 in the air) and a copper-based catalyst, which process may be referred to herein as a process of the invention (which consists of one or more embodiments).
• an oxidant e.g. a source of oxygen, for instance air and, specifically, O 2 in the air
• a copper-based catalyst which process may be referred to herein as a process of the invention (which consists of one or more embodiments).
• a salt of the compound may be employed and/or produced.
• the free base of the compound may be employed and/or produced.
• a salt form is employed and/or produced, it may be liberated to form the free base form (e.g.
• the enantioenriched compounds may be in an enantiomeric excess of greater than 40%, such as more than 60% and, in an embodiment, greater than 80% enantiomeric excess.
• the enantioenriched compounds may even be greater than 90% (for example, they may consist essentially of a single enantiomer, by which we mean that the ee may be 95% or higher, e.g. above 98% or about 100%).
• Such enantioenrichment (or ees) may be obtained directly, or through further purification techniques that are known to those skilled in the art.
• the processes of several embodiments of the invention produce products that are enantioenriched.
• the compound of formula (V) that is employed in the processes of the invention described herein (in the reaction with a compound of formula (IV) to produce a compound of formula (III)) is enantioenriched, i.e. of an ee described herein (e.g. greater than 80% ee, etc).
• downstream reactions / process steps may be
• the ee of the compound of formula (III) is linked to the ee of the precursor compound of formula (V) from which it is obtained.
• the ee of the compound of formula (I) is linked to the ee of the compound of formula (III) from which it is obtained (and so on).
• Downstream process steps may also be stereospecific and retain such stereochemistry, which is an advantage for producing final medicinal products that are single enantiomers such as ibrutinib.
• the fact that the enantioselectivity is introduced early in the reaction scheme is an advantage in terms of efficiency as less product is wasted.
• a new N-N bond is formed in the preparation of a compound of formula (I).
• a suitable copper-based catalyst(s) is employed. Such reaction is performed in the presence of an oxidant, such as O2 in the air.
• Suitable catalysts include Cu(OAc)2, CuBr and other copper halides in which the halide may be fluoro, iodo, bromo and chloro, in particular chloro and bromo (especially chloro). It may be the case that compounds of formula (II) in which X 1 represents halo (e.g.
• R 2 is as defined, and X 2 represents a halo group [in the presence of an organometallic, especially an organolithium base; in this case the lithium can exchange with the halo group (at X 2 ) so forming a nucleophile that forms a bond with the carbon atom of the cyano moiety of the compound of formula (III) ultimately forming the imine moiety of the desired compound of formula (II).
• the reaction, and the key part of forming the organolithium may be performed in the presence of a suitable solvent, such as a polar aprotic solvent e.g. THF.
• the compound of formula (III) may be prepared by reaction of a compound of formula (V),
• X 1 is as hereinbefore defined
• X3 represents a suitable leaving group such as halo (e.g. chloro, bromo or iodo) or -O-Y 2
• Y 2 represents a sulfone (e.g. -S( O )2-R y , in which Ry may represent C1-3 alkyl optionally substituted by one or more fluoro atoms, or, aryl (e.g.
• phenyl optionally substituted by one or more substituents selected from halo and C 1-3 alkyl, which latter group may itself be optionally substituted by one or more fluoro atoms
• X3 may form a sulfonate, for instance a tosylate, mesylate or triflate, with a compound of formula (VI)
• X 1 represents halo (e.g. chloro) or -O- Y 1 ;
• Y 1 represents hydrogen.
• the following compounds of formula (I) are provided in the process of the invention, those in which:
• R 2 represents phenyl (unsubstituted; so forming the appropriate substituent that is contained in ibrutinib). It is stated herein that compounds of formula (I) prepared by the processes described herein are those in which R 1 represents a nitrogen protecting group. In this respect, it will be understood that the following protecting groups are included, i.e. those that result in the formation of:
• N-alkyl e.g. N-allyl or optionally substituted N-benzyl
• N-sulfonyl e.g. optionally substituted N-benzenesulfonyl
• R 1 may represent:
• Rt1 may represent C 1-6 alkyl or optionally substituted aryl
• alkyl group is optionally substituted by one or more substituents selected from optionally substituted aryl (e.g. may form a benzyl moiety);
• Rt2 may represent optionally substituted aryl
• -C(O)ORt3 in which Rt3 may represent optionally substituted aryl or, in a further embodiment, optionally substituted C 1-6 (e.g. C 1-4 ) alkyl, e.g. tert-butyl (so forming, for example, a tert-butoxycarbonyl protecting group, i.e. when taken together with the amino moiety, a tert-butylcarbamate group) or a -CH 2 phenyl group (so forming a carboxybenzyl protecting group));
• Rt3 may represent optionally substituted aryl or, in a further embodiment, optionally substituted C 1-6 (e.g. C 1-4 ) alkyl, e.g. tert-butyl (so forming, for example, a tert-butoxycarbonyl protecting group, i.e. when taken together with the amino moiety, a tert-butylcarbamate group) or a -
• Rt4 and Rt5 independently represent hydrogen, C 1-6 alkyl, optionally substituted aryl or -C(O)Rt6, and Rt6 represents C 1-6 alkyl or optionally substituted aryl).
• R 1 represents -C(O)ORt3 (in which Rt3 may represent C 1-6 alkyl, e.g. tert-butyl) and, hence, in an aspect, the R 1 protecting group is tert-butoxycarbonyl (also known as, and referred to herein, as a BOC or Boc group).
• the choice of protecting group that R 1 may represent in the processes described herein is flexible.
• one R 1 protecting group may be converted to another in any of the compounds described herein, for instance when it is advantageous for a certain protecting group to be employed in a certain process step (and a different protecting group to be employed in a subsequent or preceding process step).
• Compounds of formula (II) that may be employed in the process of the invention e.g. to provide compounds of formula (I) in which X 1 represents halo (e.g. chloro) or -O- Y 1 ), include those in which X 1 represent halo (e.g. chloro).
• compounds of formula (II) in which X 1 represents halo e.g.
• chloro are converted (in accordance with the procedures described herein) to compounds of formula (I) in which X 1 represents halo (e.g. chloro) or -OH (i.e. -OY 1 in which Y 1 represents hydrogen).
• certain compounds of formula (I) may be converted into other compounds of formula (I), depending on the desired downstream product to be synthesised.
• a compound of formula (I) in which X 1 represents -OH it may be desired to convert such an X 1 group into a better leaving group, for instance a group in which X 1 represents -OY 1 and Y 1 represents a sulfone as hereinbefore defined (i.e.
• Such a conversion may be useful in providing further downstream products, e.g. to introduce other (more diverse array of) substituents at the X 1 position (e.g. through a nucleophilic aromatic substitution reaction).
• Such compounds of formula (I) in which X 1 represents -OY 1 in which Y 1 represents -S(O)2-Rx may be prepared from corresponding compounds in which X 1 represents -OH with a compound of formula LG-S(O) 2 - R x (in which R x is as hereinbefore defined, and LG represents a suitable leaving group such as halo, but may also represent a -OS(O) 2 -R x group, where Rx is as herein defined, and the two Rx groups may be the same or different, but are preferably the same).
• Such reactions may take place in the presence of a base and optionally a suitable solvent (e.g. they may take place in the presence of pyridine).
• compounds of formula (I) in which X 1 represents -OH may be reacted with trifluoromethanesulfonic acid anhydride, i.e. (CF 3 SO 2 ) 2 O or F 3 C-S(O) 2 -O-S(O) 2 CF 3 , e.g. in the presence of pyridine, so forming a triflate leaving group; in a similar manner other leaving groups such as mesylate and tosylate may also be formed.
• R 2 represents aryl
• phenyl may be prepared from corresponding compounds of formula (I) in which R 2 represents hydrogen, for instance by reaction of a compound of the following formula R 2a -L xa (where R 2a represents aryl, e.g. phenyl, and Lxa represents a suitable leaving or coupling group such as -B(OH) 2 , -B(OR w ) 2 or -Sn(R w ) 3 , in which each Rw independently represents a C 1-6 alkyl group, or, in the case of -B(OR w ) 2 , the respective Rw groups may be linked together to form a 4- to 6-membered cyclic group (such as a 4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl group, thereby forming e.g.
• R 2a represents aryl, e.g. phenyl
• Lxa represents a suitable leaving or coupling group
• each Rw independently represents a C 1-6
• a pinacolato boronate group and where such a group may be prepared from a corresponding compound with a halo atom), and such a reaction may be performed in the presence of a suitable catalyst system, e.g. a metal (or a salt or complex thereof) such as Pd, CuI, Pd/C, Pd(OAc) 2 , Pd(Ph 3 P) 2 Cl 2 , Pd(Ph 3 P) 4 , Pd 2 (dba) 3 and/or NiCl 2 (preferred catalysts include palladium) and a ligand such as PdCl 2 (dppf).DCM, t-Bu 3 P or the like, optionally in the presence of a suitable base (e.g.
• a suitable catalyst system e.g. a metal (or a salt or complex thereof) such as Pd, CuI, Pd/C, Pd(OAc) 2 , Pd(Ph 3 P) 2 Cl 2 , Pd(Ph 3 P
• Such compounds may be converted, for instance by reaction of such a compound of formula (I) (in which X 1 represents a relevant“leaving group”) with the following compound of formula HN(R 3 )R 4 , whereinR 3 and R 4 are as hereinbefore defined (and preferably both represent hydrogen, or at least one represents hydrogen and the other represents hydrogen or a nitrogen protecting group as hereinbefore defined.
• Protecting groups that may be mentioned include those hereinbefore defined, and in an embodiment may represent benzyl or PMB (4-methoxy-benzyl). If desired such protecting groups may be removed using methods described herein / known to those skilled in the art.
• compounds prepared in accordance with the procedures described may then be employed to prepare ibruintib.
• ibrutinib (which is prepared in an embodiment of the invention) is as follows:
• alkyl groups as defined herein may be straight-chain or, when there is a sufficient number (i.e. a minimum of three) of carbon atoms be branched-chain, and/or cyclic. Further, when there is a sufficient number (i.e. a minimum of four) of carbon atoms, such alkyl groups may also be part cyclic/acyclic. Such alkyl groups may also be saturated or, when there is a sufficient number (i.e. a minimum of two) of carbon atoms, be unsaturated (including therefore e.g.“vinyl” moieties).
• the process of the invention produces enantioenriched forms or products, by which we mean the products produced have an enantiomeric excess of greater than 20%, for instance greater than 40%, such as more than 60% and, in an embodiment, greater than 80% enantiomeric excess.
• the enantioenriched products may even be greater than 90% (for example, they may consist essentially of a single enantiomer, by which we mean that the ee may be 95% or higher, e.g. above 98% or about 100%).
• enantioenrichment (or ees) may be obtained directly, or through further purification techniques that are known to those skilled in the art. Where equivalents are referred to, for the avoidance of doubt, this is intended to mean molar equivalents.
• a process for separating the product obtained (compound of formula (I)) from the process of the invention (which may be referred to herein as the“compound of the invention”).
• the compound of the invention (or product obtained by the process of the invention) may thus be
• a pharmaceutical formulation comprising ibrutinib, which process comprises bringing into association ibrutinib (or a pharmaceutically acceptable salt thereof), which is prepared in accordance with the processes described hereinbefore, with (a) pharmaceutically acceptable excipient(s), adjuvant(s), diluents(s) and/or carrier(s).
• the processes described herein may have the advantage that the compounds prepared may be produced in a manner that utilises fewer reagents and/or solvents, and/or requires fewer reaction steps (e.g. distinct/separate reaction steps) compared to processes disclosed in the prior art.
• the process of the invention may also have the advantage that the compound(s) prepared is/are produced in higher yield, in higher purity, in higher selectivity (e.g. higher regioselectivity), in less time, in a more convenient (i.e. easy to handle) form, from more convenient (i.e. easy to handle) precursors, at a lower cost and/or with less usage and/or wastage of materials (including reagents and solvents) compared to the procedures disclosed in the prior art.
• Compound number 5 is prepared in accordance with the general procedures in the scheme below (from Compounds 1, 2, 3 and 4). Thereafter Compound 5 is converted to Compound 6 and 7 under certain conditions:
• Compound 6 is the main product with 10-20% Compound 7 as a side-product.
• the isolated yield of Compound 6 is ⁇ 55.8%.
• the 1st route involves bubbling NH 3 into a solution of Compound 6 in DMA
• This route uses a single (R)-enantiomer of starting material 2 (hereinbelow) labelled as “2R” (where downstream single enantiomers are produced, these are suffixed with“R” compared to the numbering used in schemes above)
• Example 1b is prepared by preparing an intermediate using any of the process steps described in Example 1, following by conversion to ibrutinib (or a salt thereof).
• Example B A pharmaceutical composition is prepared by first preparing ibrutinib (or a salt thereof) as per Example 2, and then contacting ibrutinib (or a salt thereof) so obtained with a pharmaceutically acceptable carrier, diluent and/or excipient.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Oncology (AREA)
• Hematology (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (1)

Family

ID=70857160

Family Applications (1)

Country Status (11)

Cited By (1)

Citations (6)

Family Cites Families (2)

• 2020
  • 2020-05-20 WO PCT/EP2020/064123 patent/WO2020234381A1/en not_active Ceased
  • 2020-05-20 BR BR112021022347A patent/BR112021022347A2/pt unknown
  • 2020-05-20 US US17/612,082 patent/US12215110B2/en active Active
  • 2020-05-20 EP EP20728440.7A patent/EP3972977A1/en active Pending
  • 2020-05-20 MX MX2021014246A patent/MX2021014246A/es unknown
  • 2020-05-20 JP JP2021569238A patent/JP7658916B2/ja active Active
  • 2020-05-20 KR KR1020217041326A patent/KR20220011668A/ko not_active Withdrawn
  • 2020-05-20 AU AU2020278162A patent/AU2020278162A1/en not_active Abandoned
  • 2020-05-20 CN CN202080037397.5A patent/CN113874378A/zh active Pending
  • 2020-05-20 CA CA3135240A patent/CA3135240A1/en active Pending
• 2021
  • 2021-11-16 IL IL288154A patent/IL288154A/en unknown

Patent Citations (6)

Non-Patent Citations (10)

Also Published As

Similar Documents

Legal Events